secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-06-18T21:04:30+00:00
Accession:  0001601830-26-000080
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Pharma 2026 annual meeting elects directors, approves exec compensation, ratifies auditor
--------------------------------------------------------------------------------

- Elected Najat Khan, Ph.D. and Franziska Michor, Ph.D. as Class II directors until 2029 annual meeting.
- Advisory vote on executive compensation passed: 206,171,008 for, 30,893,147 against, 1,280,852 abstain.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026: 361,743,500 for, 2,148,771 against, 1,128,498 abstain.
- Broker non-votes of 126,675,762 on director and compensation proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/0001601830-26-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/rxrx-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer